Selective serotonin reuptake inhibitors and benzodiazepines in panic disorder: A meta-analysis of common side effects in acute treatment
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Background: Benzodiazepines (BZs) and selective serotonin reuptake inhibitors (SSRIs) are effective in the pharmacologic treatment of panic disorder (PD). However, treatment guidelines favor SSRIs over BZs based on the belief that BZs are associated with more adverse effects than SSRIs. This belief, however, is currently supported only by opinion and anecdotes. Aim: The aim of this review and meta-analysis was to determine if there truly is evidence that BZs cause more adverse effects than SSRIs in acute PD treatment. Methods: We systematically searched Web of Science, PubMed, Cochrane Central Register of Controlled Trials, and clinical trials register databases. Short randomized clinical trials of a minimum of four weeks and a maximum of 12 weeks that studied SSRIs or BZs compared to placebo in acute PD treatment were included in a meta-analysis. The primary outcome was all-cause adverse event rate in participants who received SSRIs, BZs, or placebo. Results: Overall, the meta-analysis showed that SSRIs cause more adverse events than BZs in short-term PD treatment. Specifically, SSRI treatment was a risk factor for diaphoresis, fatigue, nausea, diarrhea, and insomnia, whereas BZ treatment was a risk factor for memory problems, constipation, and dry mouth. Both classes of drugs were associated with somnolence. SSRIs were associated with abnormal ejaculation, while BZs were associated with libido reduction. BZs were protective against tachycardia, diaphoresis, fatigue, and insomnia. Conclusion: Randomized, blinded studies comparing SSRIs and BZs for the short-term treatment of PD should be performed. Clinical guidelines based on incontrovertible evidence are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The well-built clinical question: A key to evidence-based decisions
(1995) · ACP Journal Club · doi:10.7326/acpjc-1995-123-3-a12 · Cited by 2,931
Epidemiology of anxiety disorders in the 21st century
Bandelow, B., & Michaelis, S. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.3/bbandelow · Cited by 2,079 · cited 2×
“Furthermore, a commonly exhibited opinion that addiction is a moral failing and that substance use is a choice (Stanbrook, 2012) coupled with a general tendency toward an under-recognition and under-treatment of PD (Bandelow and Michaelis, 2015) might contribute to BZs being deprecated in short-term PD treatment.”
BackgroundBaldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676 · cited 2×
“Considering that BZs have not been demonstrated to be inferior to SSRIs in terms of efficacy (American Psychiatric Association, 1998), there are two main reasons for this position: (a) the assertion that BZs induce more drug dependence than SSRIs after long-term use (Baldwin et al., 2014; Roy-Byrne et al., 2006) and (…”
BackgroundPRISMA harms checklist: improving harms reporting in systematic reviews
Zorzela, L., Loke, Y. K., Ioannidis, J. P., Golder, S., Santaguida, P., Altman, D. G., Moher, D., Vohra, S., & PRISMA harms group (2016) · BMJ · doi:10.1136/bmj.i157 · Cited by 557 · cited 1×
“…review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement extension for harms (Zorzela et al., 2016; Supplemental Material 1) and was conducted following an a priori established protocol registered with PROSPERO (CRD42018104339;…”
MethodMontejo-gonzàlez, A. L., Llorca, G., Izquierdo, J. A., Ledesma, A., Bousono, M., Calcedo, A., Carrasco, J. L., Ciudad, J., Daniel, E., De LA Gandara, J., et al. (1997) · Journal of Sex & Marital Therapy · doi:10.1080/00926239708403923 · Cited by 505
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455 · cited 1×
“Some authors advocate that the key signs of BZ dependence are withdrawal symptoms, such as tremor, dizziness, anxiety, and insomnia, on dosage reduction or discontinuation (Ashton, 2005).”
BackgroundFava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436 · cited 2×
“However, withdrawal reactions may ensue with either BZs or SSRIs (Belaise et al., 2012; Bhanji et al., 2006; Fava, 2006; Fava et al., 2015; Greenblatt et al., 1990; Nardi et al., 2010; Nielsen et al., 2012; Rickels et al., 1990; Schweizer et al., 1990).”
BackgroundCarrière, I., Fourrier-Reglat, A., Dartigues, J.-F., Rouaud, O., Pasquier, F., Ritchie, K., & Ancelin, M.-L. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.229 · Cited by 374 · cited 2×
“, 2005), substance abuse disorder (Gould, 2010), and/or sleep disturbances (Cellini, 2017), or use of concomitant medications with anticholinergic properties (Carriere et al., 2009).”
Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Cited by
Bandelow, B., Allgulander, C., Baldwin, D. S., Costa, D. L. D. C., Denys, D., Dilbaz, N., Domschke, K., Eriksson, E., Fineberg, N. A., Hättenschwiler, J., et al. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2022.2086295 · Cited by 158
Self-citationFava, G. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320970325 · Cited by 84
Davies, S. J., Rudoler, D., de Oliveira, C., Huang, A., Kurdyak, P., & Iaboni, A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069096 · Cited by 32
“A good example of such a study is the recent meta-analysis of Quagliato et al. (2019), which compared the side effect burden of benzodiazepines in panic disorder treatment trials of up to 12 weeks duration to that of SSRIs, concluding that incidence of adverse effects was slightly lower in people…”
Background
Metadata
- Authors
- Quagliato, L. A., Cosci, F., Shader, R. I., Silberman, E. K., Starcevic, V., Balon, R., Dubovsky, S. L., Salzman, C., Krystal, J. H., Weintraub, S. J., Freire, R. C., Nardi, A. E., & International Task Force on Benzodiazepines
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2019-07-15
- Volume
- 33
- Issue
- 11
- Pages
- 1340-1351
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2957219861
- Cited by
- 35
- References
- 25
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective serotonin reuptake inhibitors and benzodiazepines in panic disorder: A meta-analysis of common side effects in acute treatment. https://app.cochat.ai/papers/10.1177/0269881119859372
- The paper
- Quagliato, L. A., Cosci, F., Shader, R. I., Silberman, E. K., Starcevic, V., Balon, R., Dubovsky, S. L., Salzman, C., Krystal, J. H., Weintraub, S. J., Freire, R. C., Nardi, A. E., & International Task Force on Benzodiazepines. (2019). Selective serotonin reuptake inhibitors and benzodiazepines in panic disorder: A meta-analysis of common side effects in acute treatment. Journal of Psychopharmacology. https://doi.org/10.1177/0269881119859372
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.